Regenxbio Inc (RGNX)

Exchange
NASDAQ
Symbol
RGNX
Sector
Life Sciences
Industry
Biological Products, (no Disgnostic Substances)
Description
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Country
USA

Stock price

At close: December 20, 2024

  • Open
    7.36
  • High
    7.75
  • Low
    7.21
  • Close
    7.62
  • Volume
    10,645,200

Financial ratios

Dec 31, 2023

Activity ratios
Inventory turnover
—
Receivables turnover
3.45
Payables turnover
6.05
Working capital turnover
0.42
Days of inventory on hand (DOH)
—
Days of sales outstanding (DSO)
105.72
Number of days of payables
60.29
Fixed asset turnover
0.65
Total asset turnover
0.15
 Liquidity ratios
Current ratio
2.57
Quick ratio
2.60
Cash ratio
2.41
Cash conversion cycle
45.43
 Solvency ratios
Debt-to-assets ratio
0.00
Debt-to-capital ratio
0.00
Debt-to-equity ratio
0.00
Financial leverage ratio
1.84
Interest coverage
-39.07
 Profitability ratios
Gross profit margin
-61.19%
Operating profit margin
-313.29%
Pretax margin
-308.05%
Net profit margin
-307.87%
Operating return on assets (Operating ROA)
-46.71%
Return on assets (ROA)
-45.91%
Return on total capital
-86.01%
Return on equity (ROE)
-84.52%